Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms

The Oxford Handbook of the Economics of the Biopharmaceutical Industry

Volumn , Issue , 2012, Pages

  Harrington, Scott E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b AMERICAN ENTERPRISE INSTITUTE   (United States)

Author keywords

Biotechnology industry; Capital asset pricing model; Equity capital cost; Medical device industry; Pharmaceutical industry; Risk factor model; Systemic risk

Indexed keywords

EID: 85066386187     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780199742998.013.0004     Document Type: Chapter

References (29)

1. Bastin, V., and G. Hubner. 2006. "Concentrated Announcements on Clustered Data: An Event Study of Biotechnology Stocks." Financial Management 35: 129-157.
2. Berk, J., R. Green, and V. Naik. 2004. "Valuation and Return Dynamics of New Ventures." The Review of Financial Studies 17: 1-35.
3. Chan, K., J. Lakonishok, and T. Sougiannis. 2001. "The Stock Market Valuation of Research and Development Expenditures." Journal of Finance 56: 2431-2456.
4. Clem, A., A. Cowan, and C. Jeffrey. 2004. "Market Reaction to Proposed Changes in Accounting for Purchased Research and Development in R&DIntensive Industries." Journal of Accounting, Auditing & Finance: 19(4): 405-428.
5. Cochrane, J. 2001. Asset Pricing. Princeton, NJ: Princeton University Press.
6. Cockburn, I., and J. Lerner. 2009. The Cost of Capital for Early-Stage Biotechnology Ventures. Boston University and Harvard University. Available at http://www.slideshare.net/NVCA/the-cost-of-capital-for-early-stage-biotechnology-ventures (accessed November 2011).
7. DiMasi, J., and H. Grabowski. 2007. "The Cost of Biopharmaceutical R&D: Is Biotech Different?." Managerial and Decision Economics 28: 469-479.
8. DiMasi, J., R. Hansen, and H. Grabowski. 2003. "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics 22: 151-185.
9. DiMasi, J., R. Hansen, H. Grabowski, and L. Lasagna. 1991. "Cost of Innovation in the Pharmaceutical Industry." Journal of Health Economics 10: 107-142.
10. Eberhart, A., W. Maxwell, and A. Siddique. 2004. "An Examination of Long-Term Stock Returns and Operating Performance Following R&D Increases." Journal of Finance 59: 623-650.
11. Fama, E., and K. French. 1992. "The Cross-section of Expected Stock Returns." Journal of Finance 47: 427-455.
12. Fama, E., and K. French. 1993. "Common Risk Factors in Returns on Stocks and Bonds." Journal of Financial Economics 33: 3-56.
13. Fama, E., and K. French. 2006. "The Value Premium and the CAPM." Journal of Finance 61: 2163-2185.
14. Ellison, S., and W. Mullin. 2001. "Gradual Incorporation of Information: Pharmaceutical Stocks and the Evolution of President Clinton's Health Care Reform." Journal of Law & Economics 44: 89-129.
15. Golec, J., S. Hegde, and J. Vernon. 2005. Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending. NBER Working Paper 11229. Cambridge, MA: National Bureau of Economic Research.
16. Golec, J., and J. Vernon. 2007. "Financial Risk in the Biotechnology Industry." NBER Working Paper 13604. Cambridge, MA: National Bureau of Economic Research.
17. Grabowski, H., and J. Vernon. 1990. "A New Look at the Returns and Risks of Pharmaceutical R&D." Management Science 36: 804-821.
18. Hand, J. 2004. "The Market Valuation of Biotechnology Firms and Biotechnology R&D." In Venture Capital Contracting and the Valuation of High-Technology Firms, eds. J. McCahery and L. Renneboog. Oxford, UK: Oxford University Press: 251-280.
19. Healy, P., S. Myers, and C. Howe. 2002. "R&D Accounting and the Tradeoff Between Relevance and Objectivity." Journal of Accounting Research 40: 677-710.
20. Joos, P. 2002. Estimating Cross-sectional Differences in Market-to-Book Ratios in the Pharmaceutical Industry. Working paper. Rochester, NY: William E. Simon Graduate School of Business Administration, University of Rochester.
21. Lev, B., and T. Sougiannis. 1999. "Penetrating the Book-to-Market Black Box: The R&D Effect." Journal of Business Finance & Accounting 26: 419-449.
22. Sougiannis, T., B. Lev, and B. Sarath. 2005. "R&D Reporting Biases and their Consequences." Contemporary Accounting Research 22: 977-1026.
23. McNamara, P., and C. Baden-Fuller. 2007. "Shareholder Returns and the Exploration-Exploitation Dilemma: R&D Announcements by Biotechnology Firms." Research Policy 36: 548-565.
24. Myers, S., and Howe, C. 1997. A Life-Cycle Financial Model of Pharmaceutical R&D. Working paper. Cambridge, MA: Program on the Pharmaceutical Industry, Sloan School of Management, Massachusetts Institute of Technology.
25. Myers, S., and L. Shyam-Sunder. 1996. "Measuring Pharmaceutical Industry Risk and the Cost of Capital." In Competitive Strategies in the Pharmaceutical Industry, ed. R. Helms. Washington, DC: American Enterprise Institute: 208-237.
26. Passov, R. 2003. "How Much Cash Does Your Company Need?" Harvard Business Review 81 (November): 1-8.
27. US Congress, Office of Technology Assessment. 1993. Pharmaceutical R&D: Costs, Risks and Rewards. OTA-H-522. Washington, DC: US Government Printing Office.
28. van Dijk, M. In press. "Is Size Dead? A Review of the Size Effect in Equity Returns." Journal of Banking & Finance. Available at SSRN:http://ssrn.com/abstract=879282 (accessed November 2011).
29. Vernon, J., J. Golec, and J. DiMasi. 2010. "Drug Development Costs When Financial Risk is Measured Using the Fama-French Three-Factor Model." Health Economics Letters 19(8): 1002-1005.